Read and Download eBook Full
Author: Graham Dukes
Publisher: Edward Elgar Publishing
Published: 2014-06-27
Total Pages: 419
ISBN-13: 1783471107
DOWNLOAD EBOOKThe pharmaceutical industry exists to serve the community, but over the years it has engaged massively in corporate crime, with the public footing the bill. This readable study by experts in medicine, law, criminology and public health documents the pr
Author: Collectif
Publisher: OECD
Published: 2017-02-03
Total Pages: 239
ISBN-13: 9264266445
DOWNLOAD EBOOKThis report discusses the need for an integrated and cyclical approach to managing health technology in order to mitigate clinical and financial risks, and ensure acceptable value for money. The analysis considers how health systems and policy makers should adapt in terms of development, assessment and uptake of health technologies. The first chapter provides an examination of adoption and impact of medical technology in the past and how health systems are preparing for continuation of such trends in the future. Subsequent chapters examine the need to balance innovation, value, and access for pharmaceuticals and medical devices, respectively, followed by a consideration of their combined promise in the area of precision medicine. The final chapter examines how health systems can make better use of health data and digital technologies. The report focuses on opportunities linked to new and emerging technologies as well as current challenges faced by policy makers, and suggests a new governance framework to address these challenges.
Author: Agency for Healthcare Research and Quality/AHRQ
Publisher: Government Printing Office
Published: 2014-04-01
Total Pages: 385
ISBN-13: 1587634333
DOWNLOAD EBOOKThis User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews.
Author: Ellen F. M. 't Hoen
Publisher:
Published: 2016
Total Pages: 181
ISBN-13: 9789079700851
DOWNLOAD EBOOKMillions of people around the world do not have access to the medicines they need to treat disease or alleviate suffering. Strict patent regimes introduced following the establishment of the World Trade Organization in 1995 interfere with widespread access to medicines by creating monopolies that keep medicines prices well out of reach for many. 0The AIDS crisis in the late nineties brought access to medicines challenges to the public?s attention, when millions of people in developing countries died from an illness for which medicines existed, but were not available or affordable. Faced with an unprecedented health crisis ? 8,000 people dying daily ? the public health community launched an unprecedented global effort that eventually resulted in the large-scale availability of low-priced generic HIV medicines. 0But now, high prices of new medicines - for example, for cancer, tuberculosis and hepatitis C - are limiting access to treatment in low-, middle and high-income countries alike. Patent-based monopolies affect almost all medicines developed since 1995 in most countries, and global health policy is now at a critical juncture if the world is to avoid new access to medicines crises. 0This book discusses lessons learned from the HIV/AIDS crisis, and asks whether actions taken to extend access and save lives are exclusive to HIV or can be applied more broadly to new global access challenges.
Author: Lawrence J. Gitman
Publisher:
Published: 2024-09-16
Total Pages: 1455
ISBN-13:
DOWNLOAD EBOOKIntroduction to Business covers the scope and sequence of most introductory business courses. The book provides detailed explanations in the context of core themes such as customer satisfaction, ethics, entrepreneurship, global business, and managing change. Introduction to Business includes hundreds of current business examples from a range of industries and geographic locations, which feature a variety of individuals. The outcome is a balanced approach to the theory and application of business concepts, with attention to the knowledge and skills necessary for student success in this course and beyond. This is an adaptation of Introduction to Business by OpenStax. You can access the textbook as pdf for free at openstax.org. Minor editorial changes were made to ensure a better ebook reading experience. Textbook content produced by OpenStax is licensed under a Creative Commons Attribution 4.0 International License.
Author: OECD
Publisher: Org. for Economic Cooperation & Development
Published: 2019-01-24
Total Pages: 0
ISBN-13: 9789264307384
DOWNLOAD EBOOKThis report reviews the important role of medicines in health sytems, describes recent trends in pharmaceutical expenditure and financing, and summarises the approaches used by OECD countries to determine coverage and pricing.
Author: J. J. F. Schroots
Publisher: IOS Press
Published: 1999
Total Pages: 208
ISBN-13: 9789051993820
DOWNLOAD EBOOKHuman aging is perhaps the most complex and important subject that will be facing science and societies in the next century. Persons seem to be living longer and remaining more active than their parents and grandparents. This is leading to social and demographic shifts that must be accommodated by society. On the other hand it presents perplexing questions about the underlying processes and determinants of healthy aging. This book gives a design for research that will increase our understanding of the factors that influence healthy aging and can lead to improvements in reducing the levels of disability in the population. It's focus is on biobehavioural and psychological factors contributing to healthy aging. Since human aging is determined by many interacting conditions inside and outside of the organism, research should concentrate on ecological relationships between the human organism and its social and physical environment. Not only individual characteristics associated with aging are discussed in this book, but also their impacts on society. Living longer means most persons will have fewer years to earn money to maintain their lives in a longer retirement. How can these two forces be resolved through public policy? At the same time greater competence in the later years needs clues to ways of releasing this productivity for the benefit of society and individuals. Adding healthy life expectancy and creating as much as possible disability-free years is a goal that can only be reached through fact finding by a multidisciplinary team of scientist collaborating on an international basis. Such a team is present in the collaborators represented in this book. The information presented in 'Aging in Europe' has not been available in any single source before. In many ways this book provides a model of gaining knowledge through cooperation that should guide us in the next century and beyond.
Author: Shayne Cox Gad
Publisher: John Wiley & Sons
Published: 2008-03-11
Total Pages: 1386
ISBN-13: 0470259809
DOWNLOAD EBOOKThis handbook features contributions from a team of expert authors representing the many disciplines within science, engineering, and technology that are involved in pharmaceutical manufacturing. They provide the information and tools you need to design, implement, operate, and troubleshoot a pharmaceutical manufacturing system. The editor, with more than thirty years' experience working with pharmaceutical and biotechnology companies, carefully reviewed all the chapters to ensure that each one is thorough, accurate, and clear.
Author: Shayne Cox Gad
Publisher: John Wiley & Sons
Published: 2008-04-04
Total Pages: 857
ISBN-13: 0470259825
DOWNLOAD EBOOKWith its coverage of Food and Drug Administration regulations, international regulations, good manufacturing practices, and process analytical technology, this handbook offers complete coverage of the regulations and quality control issues that govern pharmaceutical manufacturing. In addition, the book discusses quality assurance and validation, drug stability, and contamination control, all key aspects of pharmaceutical manufacturing that are heavily influenced by regulatory guidelines. The team of expert authors offer you advice based on their own firsthand experience in all phases of pharmaceutical manufacturing.
Author: Oliver Gassmann
Publisher: Springer
Published: 2018-05-10
Total Pages: 189
ISBN-13: 3319668331
DOWNLOAD EBOOKPharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
